BiotechTube

Temozolomide + Depatuxizumab mafodotin + Placebo for ABT-414

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioblastoma

Conditions

Glioblastoma, Gliosarcoma

Trial Timeline

Jan 4, 2015 → Apr 4, 2022

NCT ID
NCT02573324

About Temozolomide + Depatuxizumab mafodotin + Placebo for ABT-414

Temozolomide + Depatuxizumab mafodotin + Placebo for ABT-414 is a phase 3 stage product being developed by AbbVie for Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02573324. Target conditions include Glioblastoma, Gliosarcoma.

What happened to similar drugs?

1 of 17 similar drugs in Glioblastoma were approved

Approved (1) Terminated (1) Active (15)
✅TemozolomideMerckApproved
🔄enzastaurin + lomustineEli LillyPhase 3
🔄DSP-7888 Dosing Emulsion + BevacizumabSumitomo PharmaPhase 3
❌Steroid eye drops + Vasoconstrictor eye drops + Ophthalmic steroid ointment + Depatuxizumab mafodotin + TemozolomideAbbViePhase 3
🔄Cediranib + Cediranib + Lomustine Chemotherapy + Placebo CediranibAstraZenecaPhase 3
🔄Cilengitide + TemozolomideMerckPhase 3
🔄Temozolomide + Pembrolizumab + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02573324Phase 3Completed

Competing Products

20 competing products in Glioblastoma

See all competitors
ProductCompanyStageHype Score
TemferonGenenta SciencePhase 1/2
26
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
PLX3397Daiichi SankyoPhase 2
27
ASP8374 + cemiplimabAstellas PharmaPhase 1
29
Nimotuzumab + TemozolomideSun PharmaceuticalPhase 2
35
Gliadel + Avastin + TemodarEisaiPhase 2
27
BCNU Wafer + Irinotecan + BevacizumabEisaiPhase 1/2
24
KHK2455Kyowa KirinPre-clinical
26
olaratumab + ramucirumabEli LillyPhase 2
35
enzastaurin + temozolomideEli LillyPhase 1/2
32
enzastaurin + bevacizumab + Enzyme-inducing antiepileptic drugs (EIAED) + Non-enzyme inducing antiepileptic drugs (NEIAED)Eli LillyPhase 2
35
Temozolomide + Neratinib + QBS10072S + Abemaciclib + CC-115Eli LillyPhase 2
42
AbemaciclibEli LillyPhase 2
39
Enzastaurin 500 milligram (mg) Once Daily (QD) + Enzastaurin 250 mg Twice Daily (BID)Eli LillyPhase 2
35
Abemaciclib + LY3214996Eli LillyPhase 1
29
enzastaurin + lomustineEli LillyPhase 3
40
Galunisertib + Lomustine + PlaceboEli LillyPhase 2
35
DSP-7888 Dosing Emulsion + BevacizumabSumitomo PharmaPhase 3
40
DSP-7888Sumitomo PharmaPhase 1/2
32
BBI608 + TemozolomideSumitomo PharmaPhase 1/2
32